

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Advani, Ranjana	POSITION TITLE Professor of Medicine/Oncology		
eRA COMMONS USER NAME (credential, e.g., agency login) ADVANI.RANJANA			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	MM/YY	FIELD OF STUDY
Bombay University, India	Premed	09/74-06/76	Physics/Chem/Bio
TN Medical College Bombay University, India	MD	09/76-06/81	Medicine
Bombay University, India		09/81-06/84	Residency: Internal Med
Santa Clara Valley Medical Ctr, San Jose, CA		07/86-06/87	Residency: Internal Med
Stanford University Medical Center, Stanford CA		07/87-06/91	Fellowship: Hematology
Stanford University Medical Center, Stanford CA		07/94-06/96	Fellowship: Oncology

A. Personal Statement

My primary research interests include improving care for non-Hodgkin lymphoma and Hodgkin lymphoma patients by optimizing front line regimens, by developing novel agents and targeted therapy for refractory and recurrent disease, by advancing correlative studies involving biomarkers, and by addressing long-term survivorship needs. I lead multi-institutional efforts as a national study Principle Investigator (PI) or Co-PI on targeted therapies, translational and imaging studies. I have spearheaded the efforts to establish the Stanford Biomarker Consortium, a unique collaborative endeavor between community oncologists and Stanford to study biomarkers in lymphoma. I collaborate as a clinical researcher on numerous interdisciplinary clinical studies that seek to advance the potential of "personalized" therapy in the clinical management of patients. Many of these projects have been focused on recent advances in understanding and characterizing the underlying biology of lymphoma with the goal better of defining risk factors and improving therapy.

B. Positions and HonorsPositions and Employment

1985-1986	Research Assistant Hematology, Stanford University Medical Center
1991-1993	Visiting Physician, Division of Oncology/Hematology, University of Tubingen Medical Center, Tubingen Germany
1996-1999	Staff Physician, Division of Oncology, Stanford University Medical Center
1999-2004	Clinical Instructor, Division of Oncology, Stanford University Medical Center
2004-2007	Assistant Professor of Medicine/Oncology, Stanford University Medical Center
2007-2011	Associate Professor of Medicine/Oncology, Stanford University Medical Center
2011-present	Professor of Medicine/Oncology, Stanford University Medical Center
2010-present	Disease Management Group, Physician Leader for Lymphoma

Other Experience and Memberships

2010-present	ASH Committee on Educational Affairs
2010-present	Scientific Advisory Board, Lymphoma Research Foundation
2010-present	NCI Lymphoma Steering Committee, T-Cell Working Group
2011	Expert Review Panel for Lymphoma Clinical Studies Group to the National Cancer Research Network (United Kingdom) Steering Group
2011-present	ASCO Cancer Education Committee

Honors

- 2006 Teaching Award for Exceptional Contributions to Education in Medicine
2009 Indian Women Empowered (IWE) Annual Award for Contributions in Medicine

C. Selected Peer-reviewed publications (Selected from 54 papers).

1. **Advani R**, Rosenberg SA and Horning SJ. (2004). Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. *J Clin Oncol* 22(8):1454-9. PMC Journal – In Process Morales AV,
2. **Advani R**, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ. (2007). Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. *J Clin Oncol* 25 (25):3902-7. PMC Journal – In Process.
3. **Advani R**, Horwitz SM, Riaz N, Reddy S, Hoppe RT and H. Kim YH. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. *J Am Acad Dermatol.* 59(6):953-7. PMC Journal – In Process.
4. Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y, Briones J, **Advani RH**, Connors JM, Byrne GE, Levy R, Gascoyne RD, Lossos IS. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. *Blood* 111(12):5509-14. PMCID: 2424149.
5. Kohrt H, Johannsen A, Hoppe R, Horning SJ, Rosenberg S, **Advani R**, and Lee P. (2009) Dynamic CD8 T cell responses to tumor-associated Epstein-Barr Virus antigens in patients with Epstein-Barr Virus negative Hodgkin's Disease. *Onc Rsch* 18(5-6), 287-292.
6. **Advani RH**, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. (2009). Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. *J Clin Oncol* 27(26):4371-7. PMC Journal – In Process
7. Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, **Advani RH**, Hoppe RT, and Kim YH. (2009). Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. *Arch Dermatol* 145(6):667-74. PMC Journal – In Process.
8. **Advani RH**, Hoppe RT, Maeda LS, Baer DM, Mason J, Rosenberg SA, and Horning SJ. (2010) Stage I-IIA non-bulky Hodgkin lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. *Int J Radiat Oncol Biol Phys.* Oct 7. [Epub ahead of print].
9. **Advani RH**, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, and Horning SJ. (2010) Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma patients treated with R-CHOP in the US intergroup study (ECOG 4494, CALGB 9793): Consideration of age greater than 70 years in an elderly prognostic index (E-IPI). *Br J Haematol.* 151 (2): 143-151.
10. Ng A, Constone LS, **Advani R**, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. (2010) ACR Appropriateness Criteria: Follow-up of Hodgkin's lymphoma. *Curr Probl Cancer* 34, 211-27.
11. Horning SJ, Juweid ME, Schode H, Wiseman G, McMillan A, Swinnen LJ, **Advani R**, Gascoyne RD, and Quon A. (2010) Interim positron emission tomography (PET) in diffuse large B cell lymphoma: Independent expert nuclear medicine evaluation of ECOG 3404. *Blood* 115(4): 775-7. PMCID: PMC2815514
12. **Advani RH**, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC. (2010) Phase 1 experience with voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. *Clin Cancer Res* 16(7): 2167-75.
13. Gratzinger D, **Advani RH**, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS, Gascoyne RD, Natkunam Y. (2010). Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). *Br J Haematol* 148(2):235-44. PMCID: PMC2809124
14. Brody JD, AicWZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim JH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, and Levy R. (2010) In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. *J Clin Oncol.* 28(28): 4324–4332.

15. **Advani RH**, Hong F, Horning SJ, Kahl BS, Manola J, Swinnen LJ, Habermann TM, Ganjoo K. (2011) Cardiac Toxicity Associated with Bevacizumab (Avastin) in Combination with CHOP Chemotherapy for Peripheral T Cell Lymphoma in ECOG 2404 Trial) Leuk Lymphoma Sep 15. [Epub ahead of print] PMC Journal – In Process.
16. Alizadeh AA, Gentles AJ, Alencar A, Liu CL, Kohrt HE, Houot R, Goldstein M, Zhao S, Natkunam Y, **Advani R**, Gascoyne RD, Briones J, Tibshirani R, Myklebust JH, Plevritis S, Lossos IS, and Levy R. Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes reflecting tumor and microenvironment. Blood. 118:1350-1358, 2011. PMC Journal – In Process.
17. Maeda LS, Lee M, and **Advani RH**. (2011) Current concepts and controversies in the management of early stage Hodgkin lymphoma. Leuk Lymphoma: 52 (6): 962-71. PMC Journal – In Process.
18. Burington B, Yue P, Shi X, **Advani RH**, Lau JT, Tan J, Stinson J, Januario T, deVos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TC, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagira S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, and Dornan D. (2011) CD40 pathway activation status predicts the anti-tumor activity of CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med. 3(74):74ra22.
19. Das P, Ng A, Constone LS, **Advani R**, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. (2011) ACR Appropriateness criteria® topic, Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol. 8(5):302-8.